PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) CEO Daniel Cohen tells Proactive it has filed an application with the FDA to receive an orphan drug designation for the use of DMT in preventing kidney injuries in patients undergoing kidney transplants. Cohen says the group aims to unlock the potential of DMT in treating unmet medical needs, and the prevention of kidney injury during transplant surgery fits is just one of many that fits in with its psychedelic pharmaceutical strategy of creating a unique portfolio of DMT therapies targeting rare disorders.
PharmaDrug pursuing Orphan Drug Designation with FDA to use DMT in kidney transplants
